Skip to main content
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. — Investor Relations & Filings

Ticker · BCAX ISIN · US0554771032 US Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2025-02-12 Major Shareholding Noti…
Country US United States of America
Listing US BCAX

About Bicara Therapeutics Inc.

https://www.bicara.com/

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class, dual-action biologics for cancer treatment. The company engineers bifunctional therapies that combine the precision of targeted treatments with the activation of a potent and durable anti-tumor immune response. This approach is designed to deliver therapeutic impact directly within the tumor microenvironment, with a primary focus on developing treatments for patients with solid tumors.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-12 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 13, 2025. It primarily announces the furnishing of a corporate presentation (Exhibit 99.1) that the company intends to use in investor meetings and will be available on its website. The text explicitly states that the presentation is being furnished and is not "filed" for certain regulatory purposes. The document does not contain actual financial statements or detailed financial analysis but rather provides a presentation for investors. According to the filing definitions, a corporate presentation intended for investors focusing on financials, strategy, and market position fits the category of Investor Presentation (IP). The document length is 3503 characters, which is relatively short but contains the presentation itself as an exhibit, not just an announcement of a report. Therefore, the best classification is Investor Presentation (IP).
2025-01-13 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2024, reporting the issuance of a press release announcing financial results for the third quarter ended September 30, 2024, and a corporate presentation. The document itself does not contain the financial results or detailed financial statements but rather furnishes these materials as exhibits. The text explicitly states that the press release and presentation are furnished and not filed, and the document is a current report notifying the market of these events. The document length is 4377 characters, which is relatively short and consistent with an announcement rather than a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS), as it is a current report announcing the release of financial results and presentation but does not contain the full financial data or analysis itself.
2024-11-12 English
SC 13G
Major Shareholding Notification
2024-09-26 English
SC 13G
Major Shareholding Notification
2024-09-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.